MiNK Therapeutics (INKT) AI Stock Analysis

• Market Cap: $56.14M
• Dividend Yield: N/A
• Average Volume (3M): 39.56K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.14
• Revenue Growth: N/A
• EPS Growth: 21.48%
• Country: US
• Employees: 23
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.65
• Shares Outstanding: 4,694,155
• 10 Day Avg. Volume: 31,712
• 30 Day Avg. Volume: 39,559
• PEG Ratio: 0.04
• Price to Book (P/B): -1.33
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -2.73
• Enterprise Value/Market Cap: 0.59
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -168.70
• Enterprise Value/Ebitda: -2.73
• 1Y Price Target: $35.00
• Price Target Upside: 192.64% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 48 Neutral
• Price Target: $12.00 ▲(0.33% Upside)

The score is primarily held down by weak financial fundamentals (pre-revenue, negative equity, and highly concerning TTM cash flow metrics). This is partially offset by a constructive earnings call centered on clinical progress and runway, while technicals and valuation provide limited additional support.

Positive Factors

Clinical Trial Success

Successful trials with AGENT-797 demonstrate the potential of MiNK's therapies to treat resistant solid tumors, enhancing long-term growth prospects.

Strategic Partnerships

Partnerships and grants provide financial support and credibility, aiding in the development of new therapies and enhancing competitive positioning.

Innovative Product Development

MiNK-215's development showcases innovation in cancer treatment, potentially offering scalable solutions and strengthening the company's product pipeline.

Negative Factors

Negative Equity

Negative equity indicates financial instability, limiting MiNK's ability to leverage assets for growth and increasing reliance on external funding.

Weak Cash Flow

Severely negative cash flow highlights dependency on external financing, posing risks to sustainability and operational continuity without revenue growth.

Increased Net Loss

Rising net losses reflect increasing operational expenses, which could strain financial resources and hinder long-term profitability if not addressed.

MiNK Therapeutics Business Overview & Revenue Model

Company Description

MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.

How the Company Makes Money

MiNK Therapeutics makes money through the research and development of its iNKT cell therapies, which are primarily funded through a combination of private investments, public offerings, and strategic partnerships. The company generates revenue by entering into collaboration agreements with larger pharmaceutical companies who are interested in its proprietary technology platform. These partnerships may include upfront payments, milestone payments based on developmental progress, and royalties on future sales if the therapies are successfully commercialized. Additionally, MiNK might receive grants or other funding from governmental and non-governmental organizations to support its research initiatives.

MiNK Therapeutics Financial Statement Overview

Summary

MiNK Therapeutics faces significant financial challenges typical of early-stage biotech companies. The absence of revenue and substantial net losses, along with negative equity in some periods, highlight financial instability. While the company has no debt, its operations are heavily reliant on external financing, and cash flow remains negative.

Income Statement

MiNK Therapeutics has consistently reported zero revenue in recent years, indicating a lack of commercialized products or services. The company has experienced substantial net losses, with a significant negative net profit margin. The EBIT and EBITDA margins are also negative, reflecting operational inefficiencies and high expenses relative to nonexistent revenues. These financial challenges suggest the company is still in a developmental phase, typical for biotechnology firms, but underscore the need for successful product development and commercialization.

Balance Sheet

The company's balance sheet indicates a challenging financial position, with negative stockholders' equity in several years, implying liabilities exceed assets. The absence of debt is positive, but the equity ratio is highly unstable, reflecting past negative equity scenarios. MiNK Therapeutics holds a substantial amount of cash and short-term investments, which might support operations in the short term. The lack of debt provides some financial flexibility, but overall, the balance sheet shows financial instability.

Cash Flow

MiNK Therapeutics has consistently experienced negative operating and free cash flows, indicating ongoing cash consumption without generating cash through operations. Financing activities have been a primary source of cash, which may not be sustainable in the long term. The company's ability to maintain operations relies heavily on external financing rather than operational success. The absence of positive cash flow from operations highlights the need for significant improvements in commercial and operational execution.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	-197.05K	-215.44K	-204.62K	-121.75K	-77.96K	-55.06K
EBITDA	-12.16M	-10.57M	-22.25M	-27.87M	-27.70M	-13.74M
Net Income	-12.36M	-10.78M	-22.46M	-27.99M	-30.21M	-16.24M
Balance Sheet
Total Assets	14.96M	5.72M	4.55M	21.47M	40.24M	4.56M
Cash, Cash Equivalents and Short-Term Investments	14.28M	4.58M	3.37M	19.64M	38.89M	2.69M
Total Debt	5.73M	4.92M	0.00	0.00	0.00	43.82M
Total Liabilities	28.48M	25.31M	22.61M	21.87M	16.47M	58.43M
Stockholders Equity	-13.51M	-19.59M	-18.06M	-401.30K	23.78M	-53.87M
Cash Flow
Free Cash Flow	-1.35B	-9.56M	-15.84M	-19.12M	-13.08M	-8.43M
Operating Cash Flow	-1.35B	-9.56M	-15.76M	-18.87M	-12.83M	-8.34M
Investing Cash Flow	0.00	0.00	-73.56K	-250.05K	-248.98K	-95.21K
Financing Cash Flow	14.12M	10.82M	-407.17K	-155.60K	49.26M	11.11M

MiNK Therapeutics Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 11.96
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For INKT, the sentiment is Neutral. The current price of 11.96 is above the 20-day moving average (MA) of 11.86, below the 50-day MA of 11.98, and below the 200-day MA of 12.20, indicating a neutral trend. The MACD of -0.03 indicates Negative momentum. The RSI at 49.87 is Neutral, neither overbought nor oversold. The STOCH value of 49.17 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for INKT.

MiNK Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ORMP	62 Neutral	$146.47M	3.67	24.38%	―	―	814.20%
ARMP	52 Neutral	$233.00M	-4.84	―	―	-7.55%	-13.09%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
INKT	48 Neutral	$56.14M	-3.94	―	―	―	21.48%
QNCX	47 Neutral	$197.67M	-2.91	-247.78%	―	―	2.26%
VERU	45 Neutral	$43.18M	-2.11	-61.92%	―	-100.00%	55.10%

MiNK Therapeutics Corporate Events

MiNK Therapeutics announces board resignation amid public appointment

On December 29, 2025, Robert Kadlec, MD, resigned from the Board of Directors of MiNK Therapeutics, Inc., including all committee roles, following his acceptance of a senior public service appointment as Assistant Secretary of War for Nuclear Deterrence and Chemical and Biological Defense Policy and Programs in the U.S. government. Dr. Kadlec, who joined the board in October 2024, had provided the company with strategic insights drawn from his extensive background in medicine, public health preparedness, and national service, and his departure reflects both the prestige of his new role and MiNK’s connections to high-level expertise, with the company publicly thanking him for his contributions and service during his tenure.

The most recent analyst rating on (INKT) stock is a Hold with a $12.00 price target. To see the full list of analyst forecasts on MiNK Therapeutics stock, see the INKT Stock Forecast page.